Survodutide
Also known as: BI 456906
Browse our Survodutide articles and comparisons. Start with the drug explainer for the mechanism and trial evidence, or choose a comparison below.
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Boehringer Ingelheim / Zealand Pharma |
| Mechanism | Dual agonist — GLP-1 + glucagon receptors |
| Administration | Once-weekly subcutaneous injection |
| Peak weight loss | ~18.7% at 46 weeks (Phase 2, 4.8 mg) |
| Status | Phase 3 for obesity and MASH |
Drug explainer
What Is Survodutide? The Dual GLP-1/Glucagon Agonist for Weight Loss and MASH →Published Phase 3 results show 12.2–13.0% average loss at 76 weeks; survodutide remains investigational for obesity and MASH.
Survodutide compared
Comparisons involving Survodutide, with the limits of comparing separate trials.
Retatrutide vs Survodutide
Two next-generation obesity drugs that both include glucagon agonism — how the triple and dual agonist approaches compare.
Updated September 8, 2026
Survodutide vs Tirzepatide (Zepbound): Glucagon vs GIP as the Second Target
Compare Phase 3 results without mixing estimands or mistaking MASH improvement for resolution.
Updated September 8, 2026
Mazdutide vs Survodutide: Two GLP-1/Glucagon Dual Agonists Compared
GLORY and SYNCHRONIZE results, liver endpoints and availability. Neither separate trials nor low discontinuation prove a tolerability advantage.
Updated September 8, 2026
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.